The war against influenza: discovery and development of sialidase inhibitors
The threat of an influenza pandemic has heightened the need for therapeutic strategies to combat this virus. This article provides a historical perspective on the discovery and development of two drugs that are at the forefront of our defences against influenza — the sialdiase inhibitors zanamivir a...
Gespeichert in:
| Veröffentlicht in: | Nature reviews. Drug discovery 2007-12, Vol.6 (12), p.967-974 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 974 |
|---|---|
| container_issue | 12 |
| container_start_page | 967 |
| container_title | Nature reviews. Drug discovery |
| container_volume | 6 |
| creator | von Itzstein, Mark |
| description | The threat of an influenza pandemic has heightened the need for therapeutic strategies to combat this virus. This article provides a historical perspective on the discovery and development of two drugs that are at the forefront of our defences against influenza — the sialdiase inhibitors zanamivir and oseltamivir — highlighting the value of structure-based drug design in this process.
The threat of a major human influenza pandemic, in particular from highly aggressive strains such as avian H5N1, has emphasized the need for therapeutic strategies to combat these pathogens. At present, two inhibitors of sialidase (also known as neuraminidase), a viral enzyme that has a key role in the life cycle of influenza viruses, would be the mainstay of pharmacological strategies in the event of such a pandemic. This article provides a historical perspective on the discovery and development of these drugs — zanamivir and oseltamivir — and highlights the value of structure-based drug design in this process. |
| doi_str_mv | 10.1038/nrd2400 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_69008483</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A623969070</galeid><sourcerecordid>A623969070</sourcerecordid><originalsourceid>FETCH-LOGICAL-c569t-621c176bcf93147ae48a31609c485e6bc82a80f05b1c369ccab16fb90ba143c3</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhiMEoh8gfgEo4tBy2eKJHX9wqyoolVbisvdo4ky2rhJ7sZNW5dfjKksrwYHKB1szz_vqHU9RvAN2Bozrzz52lWDsRXEIQokVKC1ePr6VPCiOUrphDCSo6nVxAJoJIxQcFuvNNZV3GEvcovNpKp3vh5n8L_xSdi7ZcEvxvkTflR3d0hB2I_mpDH2ZHA6uw0RZce1aN4WY3hSvehwSvd3fx8Xm29fNxffV-sfl1cX5emVraaaVrMCCkq3tDc8RkYRGDpIZK3RNua4r1KxndQuWS2MttiD71rAWQXDLj4uTxXYXw8-Z0tSMOSkNA3oKc2qkYUwLzf8LVsDBKM4y-PEv8CbM0ecZmqritTaqfoDOFmiLAzX5n8IU0ebT0ehs8NS7XD-XFTc5gXq2ALSGWmQ-C04XgY0hpUh9s4tuxHjfAGse9tzs95zJD_vAcztS98TtF5uBTwuQcstvKT5N9K_X-wX1OM2RHr3-9H8D84y5AA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223589750</pqid></control><display><type>article</type><title>The war against influenza: discovery and development of sialidase inhibitors</title><source>MEDLINE</source><source>Nature</source><source>SpringerLink Journals - AutoHoldings</source><creator>von Itzstein, Mark</creator><creatorcontrib>von Itzstein, Mark</creatorcontrib><description>The threat of an influenza pandemic has heightened the need for therapeutic strategies to combat this virus. This article provides a historical perspective on the discovery and development of two drugs that are at the forefront of our defences against influenza — the sialdiase inhibitors zanamivir and oseltamivir — highlighting the value of structure-based drug design in this process.
The threat of a major human influenza pandemic, in particular from highly aggressive strains such as avian H5N1, has emphasized the need for therapeutic strategies to combat these pathogens. At present, two inhibitors of sialidase (also known as neuraminidase), a viral enzyme that has a key role in the life cycle of influenza viruses, would be the mainstay of pharmacological strategies in the event of such a pandemic. This article provides a historical perspective on the discovery and development of these drugs — zanamivir and oseltamivir — and highlights the value of structure-based drug design in this process.</description><identifier>ISSN: 1474-1776</identifier><identifier>EISSN: 1474-1784</identifier><identifier>DOI: 10.1038/nrd2400</identifier><identifier>PMID: 18049471</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Animals ; Antiviral Agents - pharmacology ; Avian influenza ; Avian influenza viruses ; Biomedical and Life Sciences ; Biomedicine ; Biotechnology ; Cancer Research ; Care and treatment ; case-history ; Enzyme inhibitors ; Epidemics ; Health aspects ; Humans ; Influenza ; Influenza viruses ; Influenza, Human - drug therapy ; Influenza, Human - prevention & control ; Influenza, Human - virology ; Medicinal Chemistry ; Molecular Medicine ; Neuraminidase - antagonists & inhibitors ; Oseltamivir - pharmacology ; Oseltamivir phosphate ; Pathogenic microorganisms ; Peramivir ; Pharmacology/Toxicology ; Zanamivir - pharmacology</subject><ispartof>Nature reviews. Drug discovery, 2007-12, Vol.6 (12), p.967-974</ispartof><rights>Springer Nature Limited 2007</rights><rights>COPYRIGHT 2007 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Dec 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c569t-621c176bcf93147ae48a31609c485e6bc82a80f05b1c369ccab16fb90ba143c3</citedby><cites>FETCH-LOGICAL-c569t-621c176bcf93147ae48a31609c485e6bc82a80f05b1c369ccab16fb90ba143c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/nrd2400$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/nrd2400$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,2725,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18049471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>von Itzstein, Mark</creatorcontrib><title>The war against influenza: discovery and development of sialidase inhibitors</title><title>Nature reviews. Drug discovery</title><addtitle>Nat Rev Drug Discov</addtitle><addtitle>Nat Rev Drug Discov</addtitle><description>The threat of an influenza pandemic has heightened the need for therapeutic strategies to combat this virus. This article provides a historical perspective on the discovery and development of two drugs that are at the forefront of our defences against influenza — the sialdiase inhibitors zanamivir and oseltamivir — highlighting the value of structure-based drug design in this process.
The threat of a major human influenza pandemic, in particular from highly aggressive strains such as avian H5N1, has emphasized the need for therapeutic strategies to combat these pathogens. At present, two inhibitors of sialidase (also known as neuraminidase), a viral enzyme that has a key role in the life cycle of influenza viruses, would be the mainstay of pharmacological strategies in the event of such a pandemic. This article provides a historical perspective on the discovery and development of these drugs — zanamivir and oseltamivir — and highlights the value of structure-based drug design in this process.</description><subject>Animals</subject><subject>Antiviral Agents - pharmacology</subject><subject>Avian influenza</subject><subject>Avian influenza viruses</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Cancer Research</subject><subject>Care and treatment</subject><subject>case-history</subject><subject>Enzyme inhibitors</subject><subject>Epidemics</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Influenza</subject><subject>Influenza viruses</subject><subject>Influenza, Human - drug therapy</subject><subject>Influenza, Human - prevention & control</subject><subject>Influenza, Human - virology</subject><subject>Medicinal Chemistry</subject><subject>Molecular Medicine</subject><subject>Neuraminidase - antagonists & inhibitors</subject><subject>Oseltamivir - pharmacology</subject><subject>Oseltamivir phosphate</subject><subject>Pathogenic microorganisms</subject><subject>Peramivir</subject><subject>Pharmacology/Toxicology</subject><subject>Zanamivir - pharmacology</subject><issn>1474-1776</issn><issn>1474-1784</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkU1v1DAQhiMEoh8gfgEo4tBy2eKJHX9wqyoolVbisvdo4ky2rhJ7sZNW5dfjKksrwYHKB1szz_vqHU9RvAN2Bozrzz52lWDsRXEIQokVKC1ePr6VPCiOUrphDCSo6nVxAJoJIxQcFuvNNZV3GEvcovNpKp3vh5n8L_xSdi7ZcEvxvkTflR3d0hB2I_mpDH2ZHA6uw0RZce1aN4WY3hSvehwSvd3fx8Xm29fNxffV-sfl1cX5emVraaaVrMCCkq3tDc8RkYRGDpIZK3RNua4r1KxndQuWS2MttiD71rAWQXDLj4uTxXYXw8-Z0tSMOSkNA3oKc2qkYUwLzf8LVsDBKM4y-PEv8CbM0ecZmqritTaqfoDOFmiLAzX5n8IU0ebT0ehs8NS7XD-XFTc5gXq2ALSGWmQ-C04XgY0hpUh9s4tuxHjfAGse9tzs95zJD_vAcztS98TtF5uBTwuQcstvKT5N9K_X-wX1OM2RHr3-9H8D84y5AA</recordid><startdate>20071201</startdate><enddate>20071201</enddate><creator>von Itzstein, Mark</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20071201</creationdate><title>The war against influenza: discovery and development of sialidase inhibitors</title><author>von Itzstein, Mark</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c569t-621c176bcf93147ae48a31609c485e6bc82a80f05b1c369ccab16fb90ba143c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Animals</topic><topic>Antiviral Agents - pharmacology</topic><topic>Avian influenza</topic><topic>Avian influenza viruses</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Cancer Research</topic><topic>Care and treatment</topic><topic>case-history</topic><topic>Enzyme inhibitors</topic><topic>Epidemics</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Influenza</topic><topic>Influenza viruses</topic><topic>Influenza, Human - drug therapy</topic><topic>Influenza, Human - prevention & control</topic><topic>Influenza, Human - virology</topic><topic>Medicinal Chemistry</topic><topic>Molecular Medicine</topic><topic>Neuraminidase - antagonists & inhibitors</topic><topic>Oseltamivir - pharmacology</topic><topic>Oseltamivir phosphate</topic><topic>Pathogenic microorganisms</topic><topic>Peramivir</topic><topic>Pharmacology/Toxicology</topic><topic>Zanamivir - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>von Itzstein, Mark</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nature reviews. Drug discovery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>von Itzstein, Mark</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The war against influenza: discovery and development of sialidase inhibitors</atitle><jtitle>Nature reviews. Drug discovery</jtitle><stitle>Nat Rev Drug Discov</stitle><addtitle>Nat Rev Drug Discov</addtitle><date>2007-12-01</date><risdate>2007</risdate><volume>6</volume><issue>12</issue><spage>967</spage><epage>974</epage><pages>967-974</pages><issn>1474-1776</issn><eissn>1474-1784</eissn><abstract>The threat of an influenza pandemic has heightened the need for therapeutic strategies to combat this virus. This article provides a historical perspective on the discovery and development of two drugs that are at the forefront of our defences against influenza — the sialdiase inhibitors zanamivir and oseltamivir — highlighting the value of structure-based drug design in this process.
The threat of a major human influenza pandemic, in particular from highly aggressive strains such as avian H5N1, has emphasized the need for therapeutic strategies to combat these pathogens. At present, two inhibitors of sialidase (also known as neuraminidase), a viral enzyme that has a key role in the life cycle of influenza viruses, would be the mainstay of pharmacological strategies in the event of such a pandemic. This article provides a historical perspective on the discovery and development of these drugs — zanamivir and oseltamivir — and highlights the value of structure-based drug design in this process.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>18049471</pmid><doi>10.1038/nrd2400</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1474-1776 |
| ispartof | Nature reviews. Drug discovery, 2007-12, Vol.6 (12), p.967-974 |
| issn | 1474-1776 1474-1784 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69008483 |
| source | MEDLINE; Nature; SpringerLink Journals - AutoHoldings |
| subjects | Animals Antiviral Agents - pharmacology Avian influenza Avian influenza viruses Biomedical and Life Sciences Biomedicine Biotechnology Cancer Research Care and treatment case-history Enzyme inhibitors Epidemics Health aspects Humans Influenza Influenza viruses Influenza, Human - drug therapy Influenza, Human - prevention & control Influenza, Human - virology Medicinal Chemistry Molecular Medicine Neuraminidase - antagonists & inhibitors Oseltamivir - pharmacology Oseltamivir phosphate Pathogenic microorganisms Peramivir Pharmacology/Toxicology Zanamivir - pharmacology |
| title | The war against influenza: discovery and development of sialidase inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T03%3A41%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20war%20against%20influenza:%20discovery%20and%20development%20of%20sialidase%20inhibitors&rft.jtitle=Nature%20reviews.%20Drug%20discovery&rft.au=von%20Itzstein,%20Mark&rft.date=2007-12-01&rft.volume=6&rft.issue=12&rft.spage=967&rft.epage=974&rft.pages=967-974&rft.issn=1474-1776&rft.eissn=1474-1784&rft_id=info:doi/10.1038/nrd2400&rft_dat=%3Cgale_proqu%3EA623969070%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223589750&rft_id=info:pmid/18049471&rft_galeid=A623969070&rfr_iscdi=true |